Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-10-14 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司调整以简易程序向特定对象发行股票募投项目实际募集资金投入金额及使用募集资金置换预先投入自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the adjustment of actual raised funds invested in a specific project by Frontier Biopharmaceuticals (Nanjing) Co., Ltd. It discusses the amount of funds raised through a simplified procedure for a private placement of A-shares, the use of raised funds to replace pre-invested self-raised funds, and the related approvals by the board and supervisory committee. It includes references to regulatory approvals, audit verification by KPMG Huazhen, and compliance with relevant securities regulations. The document is not a full financial report but rather a verification and opinion on the use and adjustment of raised funds, which aligns with the definition of an Audit Report / Information (AR) as it involves audit verification and regulatory compliance on fundraising and fund usage. The document length is 3508 characters, which is relatively short but contains substantive content beyond a mere announcement or certification, so it is not an RPA or RNS. Therefore, the best classification is AR (Audit Report / Information). Q3 2022
2022-10-14 Chinese
前沿生物关于调整以简易程序向特定对象发行股票募投项目实际募集资金投入金额及使用募集资金置换预先投入自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding adjustments to the amount of funds raised through a simplified procedure for a specific stock issuance and the use of raised funds to replace previously self-raised funds invested in projects. It includes details about the fundraising, approvals by the board and supervisory committee, independent directors' opinions, and verification by an accounting firm. The document is a formal disclosure about capital raising and fund usage, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion of results, but rather focuses on capital/financing updates and regulatory compliance related to fundraising activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is about 4782 characters, which is sufficient for a detailed announcement but not a full annual or interim report. Hence, the classification is CAP with high confidence.
2022-10-14 Chinese
前沿生物关于第三届监事会第四次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the fourth meeting of the third Supervisory Board of a company. It details the meeting date, attendance, and voting results on various proposals related to the use and management of raised funds. The content focuses on supervisory board decisions and compliance with regulatory requirements regarding fundraising and fund usage. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal announcement of board/management decisions rather than a full report or financial filing. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short (2407 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2022-10-14 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from a sponsoring securities firm (中信证券股份有限公司) regarding the use of idle raised funds by 前沿生物药业（南京）股份有限公司 to temporarily supplement working capital. It references regulatory guidelines on the management and use of raised funds, details the original fundraising, investment projects, and the company's internal approval process. The document is a verification or audit opinion on the use of funds, not a full financial report or earnings release. It does not contain financial statements or quarterly/yearly financial results. It is a specialized audit or verification report related to fundraising usage compliance, fitting the category of Audit Report / Information (AR). The document length is under 5,000 characters, but it is not merely an announcement of a report; it contains substantive verification content. Therefore, the best classification is AR with high confidence. FY 2022
2022-10-14 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. regarding the use of temporarily idle raised funds by Frontier Biopharmaceuticals (Nanjing) Co., Ltd. for cash management. It includes specifics about the fundraising, investment projects, cash management purposes, limits, risk analysis, internal approval procedures, and the sponsor's verification opinion. The document references regulatory approvals, fundraising amounts, and compliance with listing rules. It is not a brief announcement but a comprehensive verification and opinion report related to the use of raised funds. This fits the category of a Capital/Financing Update (CAP), as it deals with fundraising and the management of raised capital, including cash management activities. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or certification. Therefore, the best classification is CAP with high confidence.
2022-10-14 Chinese
前沿生物独立董事关于第三届董事会第四次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion on several proposals related to the use and management of raised funds from a specific stock issuance. It discusses adjustments to the investment amount of the raised funds, replacement of self-raised funds with raised funds, cash management of temporarily idle raised funds, and temporary supplementation of working capital with idle raised funds. The document references compliance with regulatory guidelines and company rules but does not contain financial statements or detailed financial data. It is a formal opinion related to capital use and fundraising activities, not a full financial report or earnings release. Given the focus on fundraising and capital management, the document best fits the category of Capital/Financing Update (CAP). The document length is short (1590 characters), but it is not merely an announcement of a report publication; it contains substantive independent opinions on capital use matters.
2022-10-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.